The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 23, 2021

Filed:

Dec. 12, 2018
Applicants:

Bristol-myers Squibb Company, Princeton, NJ (US);

Domantis Limited, Middlesex, GB;

Inventors:

Steven G. Nadler, Princeton, NJ (US);

James K. Tamura, Yardley, PA (US);

Laura Price, Langhorne, PA (US);

Robert P. Rehfuss, North Wales, PA (US);

Suzanne J. Suchard, Portland, OR (US);

Anish Suri, Ekeren, BE;

James William Bryson, Langhorne, PA (US);

Aaron Yamniuk, Lawrenceville, NJ (US);

Steven Grant, Swaffham Prior, GB;

Olga Ignatovich, Cambridge, GB;

Philip Drew, Histon, GB;

Assignees:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Domantis Limited, Middlesex, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); C07K 16/46 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/18 (2013.01); C07K 16/283 (2013.01); C07K 16/2833 (2013.01); C07K 16/2875 (2013.01); C07K 16/2896 (2013.01); C07K 16/46 (2013.01); C07K 16/468 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01);
Abstract

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.


Find Patent Forward Citations

Loading…